Back to Search
Start Over
Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort
- Source :
- Clinical Immunology, CLINICAL IMMUNOLOGY, r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau, instname, Clinical Immunology (Orlando, Fla.)
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- Although the starting event in COVID-19 is a viral infection some patients present with an over-exuberant inflammatory response, leading to acute lung injury (ALI) and adult respiratory distress syndrome (ARDS). Since IL-6 plays a critical role in the inflammatory response, we assessed the efficacy and safety of tocilizumab (TCZ) in this single-centre, observational study in all Covid-19 in-patient with a proven SARS-CoV-2 rapidly progressing infection to prevent ALI and ARDS. 104 patients with COVID-19 treated with TCZ had a lower mortality rate (5·8%) compared with the regional mortality rate (11%), hospitalized patient's mortality (10%), and slightly lower than hospitalized patients treated with our standard of care alone (6%). We found that TCZ rapidly decreased acute phase reactants, ferritin and liver release of proteins. D-Dimer decreased slowly. We did not observe specific safety concerns. Early administration of IL6-R antagonists in COVID-19 patients with impending hyperinflammatory response, may be safe and effective treatment to prevent, ICU admission and further complications.
- Subjects :
- 0301 basic medicine
Male
medicine.medical_specialty
ARDS
IL-6R antagonist
Acute Lung Injury
Immunology
Lung injury
Antibodies, Monoclonal, Humanized
Cohort Studies
Fibrin Fibrinogen Degradation Products
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Tocilizumab
Cytokine release syndrome
Internal medicine
medicine
Humans
Immunology and Allergy
Letter to the Editor
Aged
Inflammation
Respiratory Distress Syndrome
Respiratory distress
business.industry
SARS-CoV-2
Mortality rate
Acute-phase protein
COVID-19
Butyrate
Regulatory T cells
Middle Aged
medicine.disease
Receptors, Interleukin-6
Survival Analysis
COVID-19 Drug Treatment
Treatment
030104 developmental biology
chemistry
Cohort
Ferritins
Female
business
Cytokine Release Syndrome
030215 immunology
Subjects
Details
- Language :
- English
- ISSN :
- 15216616
- Database :
- OpenAIRE
- Journal :
- Clinical Immunology
- Accession number :
- edsair.doi.dedup.....17dcbb404e41d948b42e93b6de6f7bd0
- Full Text :
- https://doi.org/10.1016/j.clim.2020.108631